298 related articles for article (PubMed ID: 15630049)
1. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.
Hermann M; Shaw S; Kiss E; Camici G; Bühler N; Chenevard R; Lüscher TF; Gröne HJ; Ruschitzka F
Hypertension; 2005 Feb; 45(2):193-7. PubMed ID: 15630049
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney.
Fujihara CK; Antunes GR; Mattar AL; Andreoli N; Malheiros DM; Noronha IL; Zatz R
Kidney Int; 2003 Dec; 64(6):2172-81. PubMed ID: 14633140
[TBL] [Abstract][Full Text] [Related]
4. [Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Deray G
Presse Med; 2001 Oct; 30(30):1507-12. PubMed ID: 11712212
[TBL] [Abstract][Full Text] [Related]
5. Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats.
Richter CM; Godes M; Wagner C; Maser-Gluth C; Herzfeld S; Dorn M; Priem F; Slowinski T; Bauer C; Schneider W; Neumayer HH; Kurtz A; Hocher B
J Hypertens; 2004 Jan; 22(1):191-8. PubMed ID: 15106811
[TBL] [Abstract][Full Text] [Related]
6. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
[TBL] [Abstract][Full Text] [Related]
7. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.
Dilger K; Herrlinger C; Peters J; Seyberth HW; Schweer H; Klotz U
J Clin Pharmacol; 2002 Sep; 42(9):985-94. PubMed ID: 12211224
[TBL] [Abstract][Full Text] [Related]
8. [Renal protective effects of specific cyclooxygenase-2 inhibitor in rats with subtotal renal ablation].
Kong WX; Ma J; Gu Y; Yang HC; Zuo YQ; Lin SY
Zhonghua Nei Ke Za Zhi; 2003 Mar; 42(3):186-90. PubMed ID: 12816702
[TBL] [Abstract][Full Text] [Related]
9. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
Hinz B; Dormann H; Brune K
Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
[TBL] [Abstract][Full Text] [Related]
10. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
Wang JL; Cheng HF; Shappell S; Harris RC
Kidney Int; 2000 Jun; 57(6):2334-42. PubMed ID: 10844603
[TBL] [Abstract][Full Text] [Related]
11. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
Whelton A
J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
[TBL] [Abstract][Full Text] [Related]
12. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
Buecher B; Bouancheau D; Broquet A; Bezieau S; Denis MG; Bonnet C; Heymann MF; Jarry A; Galmiche JP; Blottière HM
Anticancer Res; 2005; 25(1A):225-33. PubMed ID: 15816542
[TBL] [Abstract][Full Text] [Related]
14. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Knight S; Johns EJ
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
16. Possible involvement of aminopeptidase A in hypertension and renal damage in Dahl salt-sensitive rats.
Nomura M; Nomura S; Mitsui T; Suzuki M; Kobayashi H; Ito T; Itakura A; Kikkawa F; Mizutani S
Am J Hypertens; 2005 Apr; 18(4 Pt 1):538-43. PubMed ID: 15831365
[TBL] [Abstract][Full Text] [Related]
17. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
18. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Walter MF; Jacob RF; Day CA; Dahlborg R; Weng Y; Mason RP
Atherosclerosis; 2004 Dec; 177(2):235-43. PubMed ID: 15530895
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.
Cheng HF; Wang CJ; Moeckel GW; Zhang MZ; McKanna JA; Harris RC
Kidney Int; 2002 Sep; 62(3):929-39. PubMed ID: 12164875
[TBL] [Abstract][Full Text] [Related]
20. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
